RNA helix
D2R News

Stay informed about D2R updates by subscribing to our mailing list!

Funding Opportunities

Learn more about D2R's newly launched funding programs.

pouring liquid into a vial with a dropper

Funding Opportunities

Commercialization Priming and Major Partnerships funding programs are now accepting applications and Letters of Intent. 

students walking outside

Latest Stories

Explore event coverages, cutting-edge RNA research, inspiring research profiles, and impactful stories.

crowd participating at event

Events

Check out the latest upcoming events.

D2R | DNA to RNA 

An inclusive Canadian approach to genomic-based RNA therapeutics 

The time is now for discovery and development of genome-guided, RNA-based precision medicines for Canada and for the world. With a landmark $165 million investment from the Canada First Research Excellence Fund, McGill’s world-leading research initiative DNA to RNA (D2R) will develop revolutionary genomic-based RNA medicines for all people of Canada.

Discover the initiative

D2R's vision for Canada

Create groundbreaking medical treatments
D2R will improve health through rapid deployment of new lower cost medical treatments for previously “undruggable” pharmaceutical targets and untreated medical conditions.
Tackle societal and policy issues
D2R will address unmet clinical needs of under-served groups, including Canada’s Indigenous and immigrant populations by engaging with patients, their families and patient organizations.
Accelerate “next-generation” drug development

D2R will catalyze Canadian pharma/biotech to create a major international hub for “next-generation” drug development, industry partnerships and startups.

 

Explore the research & impact

woman in lab coat looking through a microscope

Our researchers & partners

McGill researchers have been uncovering the mechanisms and potential of RNA for over 50 years. From genomics and RNA biology to medicine and biomanufacturing, our research strengths cover the range of expertise needed to discover gene targets and develop new treatments for disease. 

Back to top